西妥昔单抗联合FOLFOX4方案治疗转移性结直肠癌临床观察

目的评价西妥昔单抗（C225）联合FOLFOX4方案治疗转移性结直肠癌（mCRC）的疗效及安全性。方法68例经病理组织学确诊的mCRC患者，随机分为两组：西妥昔单抗联合FOLFOX4方案化疗组（联合组，34例）和单用FOLFOX4方案化疗组（对照组，34例）。结果联合组治疗后总有效率为57．6％，对照组为32．3％（P〈0．05）。最常见的Ⅲ、Ⅳ度不良反应为骨髓抑制（联合组27．3％，对照组32.4％，P〉0．05）、恶心呕吐（联合组12．1％，对照组17．7％，P〉0．05）、痤疮样皮疹（只见于联合组，9．1％）。结论西妥昔单抗可提高FOLFOX4方案治疗mCRC的有效率。除皮疹之外，其他Ⅲ、Ⅳ度不良反应与单用FOLFOX4方案治疗基本相似。

Clinical observation on cetuximab(C225) with FOLFOX4 in the treatment of metastatic colorectal cancer

Objective To evaluate the efficacy and safety of cetuximab(C225) with FOLFOX4 in the treatment of metastatic colorectal cancer (mCRC). Methods 68 patients with mCRC diagnosed by pathology were randomized in two groups: cetuximab combination with FOLFOX4 chemotherapy (combined group) and FOLFOX4 chemotherapy only (control group). Results The overall response rates (RR=CR+PR)in the combined group and the control group were 57.6 % and 32.3 % with significant difference (P <0.05). Grade Ⅲ/Ⅳ toxicity were myelosuppression(27.3 % and 32.4 %, P >0.05), nausea and vomiting(12.1% and 27.7 %, P >0.05), acne-like rash (only in combined group 9.1%). Conclusion The combination of cetuximab and chemotherapy can improve treatment efficacy. Except for rash, other grade Ⅲ/Ⅳ toxicity has no difference between the two groups.